TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06734351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOA VOLUME
Description: Subcutaneous and/or Supraperiosteal Plane Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOA VOLUME
Description: Subcutaneous and/or Supraperiosteal Plane Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLUMA XC
Description: Subcutaneous and/or Supraperiosteal Plane Injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLUMA XC
Description: Subcutaneous and/or Supraperiosteal Plane Injection
Study: NCT06153004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Activity Program (HAP)
Description: HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (ADM)
Description: Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day which can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Patients who cannot tolerate fluoxetine will be switched to escitalopram.
Study: NCT05724693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)
Description: Day 1: A single dose of BEM will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)
Description: Day 1: A single dose of BEM will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)
Description: Day 1: A single dose of BEM will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)
Description: Day 1: A single dose of BEM will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)
Description: Day 1: A single dose of BEM will be administered
Study: NCT05178368

Intervention type: PROCEDURE
Intervention: Surgical/ Transcatheter aortic valve replacement
Description: The choice of intervention will be made by the local clinical team. The timing of intervention will be determined by randomisation as part of the main EASY/EVOLVED trials
Study: NCT05326854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supportive care
Description: After Medical Termination Navigation Assisted Care Program admission to the service will be held in the form of three interviews in the clinic before and after termination. The planned training will be given in three sessions and a different training module will be applied in each meeting. After the patient is discharged, three sessions will be held remotely via telephone.
Study: NCT06437444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The implementation strategy to encourage the adoption of the Care Pathway
Description: 1. Dissemination of the most novel aspects of the agreed Care Pathway via corporate mail.~2. Audit \& Feedback (A\&F) data reports, sent every two weeks, to each paediatrician on the rate of prescription of bronchodilators administered with a spacer chamber, together with the rates of the other indicators established in the pathway, in their health centre and in the rest of the centres in the participating health areas.~3. Interactive training sessions, in which epidemiological data and data on the health, economic and social impact of asthma attacks were presented, together with data on other indicators associated with the care pathway, and key messages on current treatment recommendations based on the latest clinical practice.~4. Distribution of reminder posters in paediatrics consultations, PEDs and health centers.
Study: NCT04865367

Intervention type: OTHER
Intervention: Exposure to culture media
Description: Exposure to culture media

Intervention type: OTHER
Intervention: Exposure to culture media
Description: Exposure to culture media

Intervention type: OTHER
Intervention: Exposure to culture media
Description: Exposure to culture media

Intervention type: OTHER
Intervention: Exposure to culture media
Description: Exposure to culture media
Study: NCT04873479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: Participants in the test group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, S-ketamine 0.125mg/kg (low dose) for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and S-Ketamine 0.125mg/kg/h (low dose) and continuous inhalation of sevoflurane at 2-3%.
Study: NCT06741345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Oral Suspension
Description: Suspension of genistein nanoparticles for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Oral Suspension
Description: Suspension of genistein nanoparticles for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Oral Suspension
Description: Suspension of genistein nanoparticles for oral administration
Study: NCT06760754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Digital culinary medicine intervention
Description: Participants will receive 30lbs of healthy foods through an on-site hospital-base food pantry
Study: NCT04873479

Intervention type: OTHER
Group type: OTHER
Intervention: saline
Description: Participants in the control group received midazolam 0.05-0.1mg /kg, sufentanil 0.1-0.2ug/kg,Etomidate 0.1-0.2mg/kg, cisatracurium 0.15-0.3mg/kg, saline 0.125ml/kg for Anesthesia induction, followed by an infusion of remifentanil 0.05-0.15ug/kg/min and saline 0.125ml/kg/h and continuous inhalation of sevoflurane at 2-3%.
Study: NCT05922865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KNEESUP smart knee assistive device + KNEESUP care APP
Description: In KNEESUP smart knee assistive device + KNEESUP care APP group, participants used the KNEESUP intelligent knee assistive device. Participants wore a knee brace with a sensor module on one side of the leg, the sensor could connect with the KNEESUP care APP which were installed in participant's mobile phone. The APP was designed with an individualized exercise program and the knee brace sensor could detect the action moment of the participants during exercise. This equipment could help the participants to achieve professional-level home rehabilitation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KNEESUP care APP
Description: In KNEESUP care APP group, the participants only used the KNEESUP care APP which was installed in the mobile phone. The APP was designed with an individualized exercise program. Participants could follow the APP to do the exercise program according to their own conditions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy consulation
Description: In Healthy consulation group, participants received routine outpatient health education.
Study: NCT06182592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal cytarabine-daunorubicin for injection
Description: First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7+3 (cytarabine and daunorubicin)
Description: First induction: 7+3 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1, 2, and 3.~Second induction: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2.~Consolidation therapy: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2.
Study: NCT05849870

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frailty care pathway for older people in a rural primary care setting
Description: This intervention will take place in different primary care providers in a rural environment. Each provider will have one intervention and a no-intervention group, which will be part of the feasibility evaluation. The intervention will comprise a consultation with the participant, based on the different approaches described in the arm descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty care pathway for older people in a rural primary care setting
Description: This intervention will take place in different primary care providers in a rural environment. Each provider will have one intervention and a no-intervention group, which will be part of the feasibility evaluation. The intervention will comprise a consultation with the participant, based on the different approaches described in the arm descriptions.
Study: NCT06772064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin (drug)
Description: Rifaximin 0.4g bid for 2 weeks
Study: NCT06774833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-initiated perturbation-based balance training
Description: This group will receive two 30-minute training sessions over two weeks, with one session per week. Participants will be required to recover their balance upon self-initiated perturbation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional balance training
Description: This group will receive two 30-minute training sessions over two weeks, with one session per week. Participants will be instructed to perform balance and strength training. The same training duration and format will be used as the Self-initiated perturbation-based balance training group.
Study: NCT06774040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etribnabdione 25 mg BID
Description: The trial will start with the lower dose. When the 12 patients have been treated for 3 months and the PK and safety data are evaluated by the regulatory authority, the Sponsor and the site investigators, the high dose (50 mg BID) will be released.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etribnabdione 50 mg BID
Description: The treatment will start when the regulatory authority, the sponsor and the site investigators have reviewed the low dose safety and pharmacokinetics data.
Study: NCT05849870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty care pathway for older people in a rural primary care setting
Description: This intervention will take place in different primary care providers in a rural environment. Each provider will have one intervention and a no-intervention group, which will be part of the feasibility evaluation. The intervention will comprise a consultation with the participant, based on the different approaches described in the arm descriptions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty care pathway for older people in a rural primary care setting
Description: This intervention will take place in different primary care providers in a rural environment. Each provider will have one intervention and a no-intervention group, which will be part of the feasibility evaluation. The intervention will comprise a consultation with the participant, based on the different approaches described in the arm descriptions.
Study: NCT05501600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: Experimental acute pain stimulus will be delivered using an electric nerve stimulator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: Subjects will receive an intravenous infusion of lidocaine for about 30 minutes.
Study: NCT01120119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcitriol
Study: NCT05029063

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivaroxaban 10 MG
Description: Identical comparator drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: Identical comparator drug
Study: NCT06000358

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopic cryotherapy
Description: The cryotherapy procedure is performed before the start of systemic treatment, under visual (for endobronchial cryotherapy) or radial EBUS and fluoroscopy control (for transbronchial cryotherapy), ensuring the correct position of the cryoprobe in the tumor. After being placed in the correct position. After being placed in the correct position, the cryoprobe is cooled using CO2 and allowed to cool passively. The cooling-thawing stages are repeated for a total of 3 cycles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopic cryotherapy
Description: The cryotherapy procedure is performed before the start of systemic treatment, under visual (for endobronchial cryotherapy) or radial EBUS and fluoroscopy control (for transbronchial cryotherapy), ensuring the correct position of the cryoprobe in the tumor. After being placed in the correct position. After being placed in the correct position, the cryoprobe is cooled using CO2 and allowed to cool passively. The cooling-thawing stages are repeated for a total of 3 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: As a standard of care, patients will receive pembrolizumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: As a standard of care, patients will receive pembrolizumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: As a standard of care, patients will receive pembrolizumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: As a standard of care, patients will receive pembrolizumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum based chemotherapy
Description: As a standard of care, patients will receive platinum-based chemotherapy in addition to pembrolizumab if PD-L1 expression is less than 50%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum based chemotherapy
Description: As a standard of care, patients will receive platinum-based chemotherapy in addition to pembrolizumab if PD-L1 expression is less than 50%.
Study: NCT06773481

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BC008-1A
Description: Biological: 900 mg BC008-1A will be intravenously injected once every 3 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BC008-1A
Description: Biological: 1200 mg BC008-1A will be intravenously injected once every 3 weeks.
Study: NCT06773338

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tetris
Description: Randomly selected participants (migrants) are asked to play Tetris for at least 15 minutes on several occasions. These participants are asked while playing Tetris to try and remember bad events that recently happened to them. The participants play the classic version of the Tetris game directly on their mobile phone.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Participants do not receive any intervention.
Study: NCT06774235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Gamma 1-b
Description: injection of interferon gamma 1-b

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of placebo in the same condition of experimental traitment
Study: NCT06770816

Intervention type: OTHER
Intervention: Echocardiography
Description: HR, MAP, SBP and DBP will be recorded at baseline and 15 minutes after ESP block. Cardiac output (CO) will be calculated using echocardiographic data on stroke volume (SV) (measured from the LV outflow tract) and multiplied by HR. Changes in LV systolic function will be assessed with three parameters: fractional shortening (FS), ejection fraction (EF) using the Simpson method and S' wave of tissue Doppler imaging (TDI) of the mitral annulus (average of values at the medial and lateral annulus). LV diastolic function will be assessed with three parameters and interpreted according to the European Association of Cardiovascular Imaging guidelines. Pulsed wave (PW) Doppler of trans-mitral flow will be used to obtain the ratio between early (e) and late (atrial, a) waves. A PW Doppler between the LV outflow tract and the mitral valve will be performed to estimate the iso-volumetric relaxation time IVRT. TDI will be used to investigate myocardial relaxation at the mitral annular level (ear
Study: NCT06774196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy Group
Description: Includes Cognitive Behavioral Therapy (CBT), relaxation techniques, and biofeedback.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Group
Description: Includes pharmacological treatment (e.g., NSAIDs, muscle relaxants) and physical therapy interventions
Study: NCT06770517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: The exposure therapy will be given by the mental health care nurses (MHN) working in primary care centres. In addition, there will be eight sessions spread over 12 weeks. The first session will be 60 minutes long and the rest will be 30 minutes long.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The Usual Care group will receive care based on the general practitioners guidelines for anxiety disorders in the primary care center. This will entail possible medication, e-learning or psycho-education, problem solving therapy or a referral to a mental health institution.
Study: NCT05680532

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black raspberry
Description: Experimental group subjects were requested to take 50 g of Black Raspberry powder for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group subjects were requested to take 50 g of dextrin for 4 weeks.
Study: NCT05919602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visualization of an image catalogue
Description: Participants in the intervention group will be shown a catalog consisting of 8 images, each for 8 seconds, 25 minutes before entering the operating room. The images shown will be landscapes and/or objects of nature as an expression of neutrality, with light and soft colors, and will be chosen by over 50% of the research team from a gallery of 20 possible images that meet the aforementioned requirements.
Study: NCT05147233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Placebo
Description: Placebo comparator
Study: NCT06194591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NephrospecTM, low-intensity extracorporal shockwave therapy device
Description: Patients will receive 6 Li-ESWT treatments with the NephrospecTM device over three consecutive weeks, with a minimal recess of 24 hours between treatments and a maximum of 3 sessions per week.~Three hundred shockwaves will be applied by the PI or co-PI to each one of 8 pre-selected regions of each kidney, under ultrasound control, with the patient in the prone position. No local anaesthesia is needed. Total treatment time of one session is 30 minutes. The participant will remain under supervision for another 30 minutes and will be discharged hereafter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NephrospecTM, low-intensity extracorporal shockwave therapy device
Description: Patients will receive 6 Li-ESWT treatments with the NephrospecTM device over three consecutive weeks, with a minimal recess of 24 hours between treatments and a maximum of 3 sessions per week.~Three hundred shockwaves will be applied by the PI or co-PI to each one of 8 pre-selected regions of each kidney, under ultrasound control, with the patient in the prone position. No local anaesthesia is needed. Total treatment time of one session is 30 minutes. The participant will remain under supervision for another 30 minutes and will be discharged hereafter.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-Device
Description: The sham device is the NephrospecTM applicator with an internal barrier to prevent shockwaves to pass through to the patient.
Study: NCT05994378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280；Ganirelix Acetate Injection simulant
Description: SHR7280 200mg Q12h and Ganirelix Acetate Injection simulant 0.5mL qd;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR7280 simulant； Ganirelix Acetate Injection
Description: SHR7280 simulant 200mg Q12h and Ganirelix Acetate Injection 0.5mL:0.25mg qd;
Study: NCT06322875

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant type III humanized collagen solution for injection
Description: Each subject will receive one injection of Recombinant type III humanized collagen solution for injection on the whole face

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recombinant type III humanized collagen solution for injection
Description: Each subject will receive one injection of Recombinant type III humanized collagen solution for injection on the whole face

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinCeuticals recombinant humanized collagen (RHC) serum
Description: Subjects received SkinCeuticals recombinant humanized collagen (RHC) serum application on the test side face

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular face cream smear
Description: Subjects received Regular face cream smear application on the whole face

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular face cream smear
Description: Subjects received Regular face cream smear application on the whole face
Study: NCT06439368

Intervention type: DRUG
Group type: OTHER
Intervention: Dezocine
Description: At the end of the operation, dezocine 1.0 mg/kg + sufentanil 2.0 ug/kg (prepared as 200 ml, background volume 2 ml/h, single dose 2 ml/time, locking time 15 min) was uniformly administered by PCIA; 3 ml test dose was administered immediately after the analgesic pump was connected at the end of the operation, and continuous analgesia was performed for 48 hours after the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dezocine
Description: At the end of the operation, dezocine 1.0 mg/kg + sufentanil 2.0 ug/kg (prepared as 200 ml, background volume 2 ml/h, single dose 2 ml/time, locking time 15 min) was uniformly administered by PCIA; 3 ml test dose was administered immediately after the analgesic pump was connected at the end of the operation, and continuous analgesia was performed for 48 hours after the operation.
Study: NCT05776849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flipped classroom
Description: Educational presentation, visuals and videos (her own video explaining episiotomy application and repair and other videos shared with the traditional group) prepared for the students on episiotomy were shared one week before the episiotomy application.